Paramyxoviridae Infections - 25 Studies Found Completed : Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children : Paramyxoviridae Infections Virus Diseases : 2009-11-25 : Drug: rHPIV3cp45 10^5 TCID50 n Completed : Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults : Paramyxoviridae Infections Virus Diseases : 2006-08-17 : Biological: rB/HPIV3 Live atte Completed : Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants : Paramyxoviridae Infections Virus Diseases : 2006-03-28 : Biological: rHPIV3cp45 Placebo Active, not recruiting : The Respiratory Protection Effectiveness Clinical Trial : Influenza Respiratory Syncytial Viruses Device: N95 Respirator Partici Completed : Surveillance Study of Viral Infections Following Lung Transplantation : Lung Transplantation Bronchiolitis Obliterans Epstein-Barr : 2008-06-17 Completed : An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection : Parainfluenza : 2013-07-11 : Drug: DAS181-F02 Dry Powder in Bulk Active, not recruiting : A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen : Parainfluenza : 2012-07-17 : Drug: DAS181 dry powder, formulation F02 D Completed : Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children : Parainfluenza Virus 3, Human : 2010-12-02 : Biological: rHPIV3cp45 Vaccine Completed : Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants : Human Parainfluenza Virus 2 : 2010-06-07 : Biological: Standard Dose HPIV2 Vaccine Completed : A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants : Healthy : 2008-05-23 : Biological: MEDI-534, Cohort 1 Next >>>